Financials data is unavailable for this security.
View more
Year on year Cisen Pharmaceutical Co Ltd grew revenues 9.75% from 4.07bn to 4.46bn while net income improved 48.92% from 350.07m to 521.34m.
Gross margin | 58.78% |
---|---|
Net profit margin | 12.34% |
Operating margin | 13.73% |
Return on assets | 7.49% |
---|---|
Return on equity | 9.37% |
Return on investment | 9.20% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Cisen Pharmaceutical Co Ltd fell by 60.04m. However, the company earned 451.24m from its operations for a Cash Flow Margin of 10.11%. In addition the company used 378.13m on investing activities and also paid 133.80m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 12.83 |
---|---|
Tangible book value per share | 12.37 |
More ▼
Balance sheet in CNYView more
Current ratio | 3.56 |
---|---|
Quick ratio | 2.96 |
Total debt/total equity | 0.0586 |
---|---|
Total debt/total capital | 0.0551 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 30.15% and 48.92%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 2.27% |
---|---|
Div growth rate (5 year) | 10.72% |
Payout ratio (TTM) | 37.42% |
EPS growth(5 years) | 0.6977 |
---|---|
EPS (TTM) vs TTM 1 year ago | 22.72 |
More ▼